AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)

Loading prices

Bill Tracker · Oklahoma

HB3174

Public health; providing for the establishment of statewide investigational new drug applications for psilocybin clinical trials; effective date.

Status

Did not pass; died when the session ended

2022 Session

IntroducedFeb 7, 2022 (done)
PassedDid not happen (skipped)
SignedDid not happen (skipped)
Law in effectDid not happen (skipped)

Sponsor: Logan Phillips (Republican)
Type: Clinical Research
Substances: Psilocybin

Official text

Summary (from PoliPsy)

Public health; providing for the establishment of statewide investigational new drug applications for psilocybin clinical trials; effective date.

The full bill text and every version are kept by the legislature. We link to it rather than copy it so readers always see the current version.

Read the full bill text

Source: oklegislature.gov

Legislative history

February 8, 2022
Referred
February 8, 2022
Referred
February 7, 2022
Introduced

Loading bill…